Cargando…
Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
Tamoxifen is used to prevent and treat estrogen-dependent breast cancer. It is described as a prodrug since most of its antiestrogen effects are exerted through its hydroxylated metabolites 4-OH-tamoxifen and endoxifen. In prior work, we correlated optimal plasma levels of these metabolites with cer...
Autores principales: | Romero-Lorca, Alicia, Novillo, Apolonia, Gaibar, María, Bandrés, Fernando, Fernández-Santander, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503404/ https://www.ncbi.nlm.nih.gov/pubmed/26176234 http://dx.doi.org/10.1371/journal.pone.0132269 |
Ejemplares similares
-
Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
Publicado: (2015) -
Pharmacogenetics of ugt genes in North African populations
por: Gaibar, M., et al.
Publicado: (2018) -
Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017) -
The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety
por: Ching, Nathan R, et al.
Publicado: (2018) -
Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver
por: Sutliff, Aimee K., et al.
Publicado: (2019)